Advertisement

Malaria Journal

, 19:21 | Cite as

Associations between red blood cell variants and malaria among children and adults from three areas of Uganda: a prospective cohort study

  • Elijah KakandeEmail author
  • Bryan Greenhouse
  • Francis Bajunirwe
  • Chris Drakeley
  • Joaniter I. Nankabirwa
  • Andrew Walakira
  • Samuel L. Nsobya
  • Agaba Katureebe
  • John Rek
  • Emmanuel Arinaitwe
  • Philip J. Rosenthal
  • Moses R. Kamya
  • Grant Dorsey
  • Isabel Rodriguez-Barraquer
Open Access
Research

Abstract

Background

Multiple red blood cell (RBC) variants appear to offer protection against the most severe forms of Plasmodium falciparum malaria. Associations between these variants and uncomplicated malaria are less clear.

Methods

Data from a longitudinal cohort study conducted in 3 sub-counties in Uganda was used to quantify associations between three red blood cell variants Hb [AA, AS, S (rs334)], alpha thalassaemia 3.7 kb deletion, and glucose-6-phosphate dehydrogenase deficiency A—(G6PD 202A genotype) and malaria incidence, parasite prevalence, parasite density (a measure of anti-parasite immunity) and body temperature adjusted for parasite density (a measure of anti-disease immunity). All analyses were adjusted for age, average household entomological inoculation rate, and study site. Results for all variants were compared to those for wild type genotypes.

Results

In children, HbAS was associated, compared to wild type, with a lower incidence of malaria (IRR = 0.78, 95% CI 0.66–0.92, p = 0.003), lower parasite density upon infection (PR = 0.66, 95% CI 0.51–0.85, p = 0.001), and lower body temperature for any given parasite density (− 0.13 ℃, 95% CI − 0.21, − 0.05, p = 0.002). In children, HbSS was associated with a lower incidence of malaria (IRR = 0.17, 95% CI 0.04–0.71, p = 0.02) and lower parasite density upon infection (PR = 0.31, 95% CI 0.18–0.54, p < 0.001). α−/αα thalassaemia, was associated with higher parasite prevalence in both children and adults (RR = 1.23, 95% CI 1.06–1.43, p = 0.008 and RR = 1.52, 95% CI 1.04–2.23, p = 0.03, respectively). G6PD deficiency was associated with lower body temperature for any given parasite density only among male hemizygote children (− 0.19 ℃, 95% CI − 0.31, − 0.06, p = 0.003).

Conclusion

RBC variants were associated with non-severe malaria outcomes. Elucidation of the mechanisms by which they confer protection will improve understanding of genetic protection against malaria.

Keywords

Red blood cell variants Erythrocyte Malaria Plasmodium Sickle hemoglobin Thalassemia 

Abbreviations

G6PD

glucose-6-phosphate dehydrogenase

HbAS

haemoglobin AS genotype

HbSS

haemoglobin SS genotype

HbS

haemoglobin S genotype

PCR

polymerase chain reaction

LAMP

loop mediated isothermal amplification

GAMS

generalized additive models

aEIR

annual entomological inoculation rate

Background

Multiple red blood cell (RBC) variants are associated with protection against severe Plasmodium falciparum malaria. Studies conducted in numerous populations have consistently shown that people with HbAS have a 70–90% reduced risk of severe malaria [1, 2, 3, 4]. Similarly, both α−/αα and α−/α− thalassaemia reduce the risk of severe malaria by 20–40% [5, 6, 7]. The association between glucose-6-phosphate dehydrogenase [G6PD] deficiency and severe malaria is less clear [4, 8]. Some studies reported that G6PD protects both heterozygous females and hemizygous males from severe malaria [9], others reported protection for only hemizygous males [10], and others reported no protection [8]. Mechanisms through which these variants confer protection appear to be complex and may include restriction of red blood cell invasion and intracellular growth, increased destruction of parasitized red cells, and improved cell mediated and humoral immune responses [11, 12, 13, 14, 15, 16, 17].

While protective associations between certain RBC variants and severe malaria have been shown consistently [7, 18], associations with uncomplicated malaria have been less straightforward. Multiple studies showed reduced risk of malaria [19, 20, 21, 22, 23, 24] and lower parasite densities [4, 25, 26] with HbAS compared to wild-type. For alpha thalassaemia, studies suggested both protection against and enhancement of malaria [5, 6, 27, 28]. For G6PD deficiency, studies in Africa [29, 30, 31, 32], but not Asia [8, 33, 34, 35] suggested protection against uncomplicated malaria. Some discrepancies in findings might be attributed to differences between studies in human populations, transmission settings, and study designs.

Data from three cohorts conducted in areas of low, moderate, and high malaria transmission intensity in Uganda was used to quantify associations between three red blood cell variants and uncomplicated malaria outcomes. Notably, the cohort studies included passive surveillance for symptomatic malaria, active surveillance for P. falciparum infection, and regular entomological surveys to quantify transmission risk.

Methods

Study design, sites, and population

Prospective cohort studies were conducted at three sites. Study sites were Walukuba, Jinja District, a peri urban area in South Central Uganda with a low malaria transmission intensity (annual entomological inoculation rate (aEIR) or number of infective mosquito bites per person per year = 2.8); Kihihi, Kanungu District, a predominantly rural area in south western Uganda with moderate malaria transmission (aEIR = 32); and Nagongera, Tororo District, a predominantly rural area in south eastern Uganda with a very high transmission intensity (aEIR = 310) [36] until initiation of indoor residual spraying of insecticide in late 2014 [37]. Details on how the study households and participants were selected has been described elsewhere [36]. Briefly, in each of the 3 sub-counties 100 households were randomly enrolled. Households were included if they had at least one child between 6 months and 10 years of age and at least one adult resident providing informed consent. All children and one adult primary care giver from each household meeting the eligibility criteria were invited to participate. Participants were followed-up until they reached 11 years of age or until they were withdrawn from the study either voluntarily or because they failed to comply with study visits.

Study procedures and follow-up

Study procedures and follow up have been described in detail [36, 37, 38]. Briefly, all participants were given an insecticide treated bed net at enrollment and were followed for all their healthcare needs at dedicated study clinics open 7 days each week. Participants were provided free health care and clinic travel expenses, but received no other incentives to participate. Episodes of malaria were diagnosed by passive case detection and defined as a history of fever within the past 24 h or an elevated temperature (≥ 38.0 ℃ tympanic) with a positive malaria thick blood smear. Episodes of malaria were treated with artemether-lumefantrine (uncomplicated malaria) or intravenous quinine or artesunate (complicated malaria), following national guidelines at the time of the studies. In addition, participants were asked to make a routine visit to the study clinic every 3 months. At each of these visits, a thick blood smear was evaluated to assess for parasitaemia. The cohorts were dynamic, such that all newly eligible children were enrolled, and participants were withdrawn when they reached 11 years of age.

Household level EIR was estimated using data from entomologic surveys carried out concurrently with the cohort studies, as previously described [39]. Briefly, one CDC light trap collection was carried out monthly in the main sleeping room of each house. The average household EIR was calculated as the average number of female Anopheles mosquitoes collected per night multiplied by the proportion of mosquitoes containing sporozoites at each site.

Laboratory methods

Presence of three RBC variants, the sickle locus (rs334), − 3.7α− thalassemia and G6PD-G202A (rs1050828), was tested as previously described [40]. Briefly, genes of interest were amplified, amplicons subjected to mutation-specific restriction endonuclease digestion (for sickle haemoglobin and G6PD deficiency), reaction products resolved by electrophoresis, and genotypes determined based on the sizes of reaction products. For assessment of parasitaemia, thick blood smears were stained with 2% Giemsa, allowed to dry for 30 min, and read by experienced laboratory technologists. Parasite densities were calculated by counting the number of asexual parasites per 200 leukocytes or per 500 leukocytes if the count was less than 10 asexual parasites per 200 leukocytes, assuming a leukocyte count of 8000 per microlitre [41]. A blood smear was considered negative if the examination of 100 high power fields did not reveal any asexual parasites. For quality control, blood smears were read by a second microscopist, and discrepancies resolved by a third microscopist.

Statistical methods

All data were collected using standardized forms and subsequently entered into Microsoft access before transfer to STATA (Version 14; STATA Corp., College Station, TX, USA) and R for analyses [42]. The data analysed were for participants enrolled from August 2011 through December 2014 and followed through June 2016. Study participants were included in the analyses if they had results for at least one RBC variant tested and at least 2 months of follow-up. Associations between RBC variants and malaria incidence were quantified using negative binomial regression models with measures of association expressed as the incidence rate ratio (IRR). Associations between RBC variants and parasite prevalence at the time of each routine visit were quantified using log-binomial generalized estimating equations with robust standard errors to generate prevalence ratios (PR). Effects of RBC variants on two components of anti-malarial immunity, anti-parasite immunity (ability to control parasite densities upon infection) and anti-disease immunity (ability to tolerate higher parasite density without developing fever) were also investigated. To model these outcomes, generalized additive models (GAMS) were used as previously described [38]. The outcome of interest in the anti-parasite immunity model was the log10 parasite density in parasite positive visits, and the outcome of interest in the anti-disease model was the measured temperature, adjusted for parasite density. All analyses were adjusted for age, average household level EIR, and study site, and included random effects at the individual and household level to account for clustering. For each RBC variant, the group with wild type genotype was chosen as the reference.

Results

Characteristics of participants in the study

Of 1344 participants enrolled in the cohort studies, 1322 (98.4%) were included in the analyses and 782 of these (59.2%) were followed through the end of June 2016 (Fig. 1). A total of 1010 (76.4%) participants were children 0.5–10 years of age and 312 (23.6%) were adult primary care givers. Approximately half the children and 94% of adults were female (Table 1). Overall, the prevalence of all 3 red blood cell variants, Hb variant, alpha thalassaemia, and G6PD deficiency were highly variable across the three sites with Nagongera having the highest prevalence and Kihihi the lowest (Additional file 1: Table S1).
Fig. 1

Flow diagram of participants included in the analyses

Table 1

Baseline characteristics of participants included in the analyses

Characteristic

Children, n (%)a

Adults, n (%)a

Study site

 Walukuba

318 (31.5%)

113 (36.2%)

 Kihihi

357 (35.4%)

95 (30.5%)

 Nagongera

335 (33.2%)

104 (33.3%)

Gender

 Male

516 (51.1%)

19 (6.1%)

 Female

494 (48.9%)

293 (93.9%)

Haemoglobin variant

 AA

808 (80.7%)

242 (78.3%)

 AS

188 (18.8%)

67 (21.7%)

 SS

5 (0.5%)

0 (0%)

 No result

9

3

Alpha thalassaemia variant

 Normal

585 (60.3%)

200 (66.0%)

 α−/αα

335 (34.5%)

84 (27.7%)

 α−/−α

50 (5.2%)

19 (6.3%)

 No result

40

9

G6PD genotype (male)

 Normal

455 (89.4%)

15 (79.0)

 Hemizygotes

54 (10.6%)

4 (21.1%)

 No result

7

0

G6PD genotype (female)

 Normal

370 (75.5%)

232 (79.5%)

 Heterozygotes

108 (22.0%)

55 (18.8%)

 Homozygotes

12 (2.4%)

5 (1.7%)

 No result

4

1

aProportion among those with results available

Associations between RBC variants and malaria incidence

The overall incidence of malaria across the 3 sites was 1.60 episodes per person year (PPY) among children and 0.31 episodes PPY among adults. Among children, HbAS was associated with a 22% lower incidence of malaria (IRR = 0.78, 95% CI 0.66–0.92, p = 0.003) and HbSS with an 83% lower incidence of malaria (IRR = 0.17, 95% CI 0.04–0.71, p = 0.02), compared to children with wild type genotypes (Table 2). In contrast, among adults there was no association between HbAS and malaria incidence (IRR = 0.99, 95% CI 0.66–1.49, p = 0.98). For both children and adults there were no significant associations between alpha thalassaemia or G6PD deficiency and malaria incidence (Table 2).
Table 2

Associations between RBC variants and malaria incidence

Age group

Red cell variants

Variant

Malaria episodes

Person years of follow-up

Incidence of malaria PPY

Unadjusted

Adjusted*

IRR (95% CI)

p-value

IRR (95% CI)

p-value

Children

Haemoglobin variant

AA

4612

2762

1.67

Reference

Reference

AS

818

620

1.32

0.77 (0.64–0.94)

0.009

0.78 (0.66–0.92)

0.003

SS

3

13.4

0.22

0.16 (0.03–0.78)

0.02

0.17 (0.04–0.71)

0.02

Alpha thalassaemia variant

Normal

3233

2061

1.57

Reference

Reference

α−/αα

1769

1106

1.60

1.00 (0.85–1.18)

0.98

1.04 (0.91–1.20)

0.56

α−/−α

251

150

1.67

0.97 (0.68–1.38)

0.88

1.19 (0.87–1.62)

0.27

G6PD genotype

Normal (male)

2680

1597

1.68

Reference

Reference

Hemizygotes

374

170

2.20

1.18 (0.85–1.63)

0.33

0.93 (0.71–1.22)

0.61

Normal (female)

1768

1224

1.44

Reference

Reference

Heterozygotes

484

355

1.36

0.91 (0.70–1.18)

0.46

0.80 (0.63–1.01)

0.06

Homozygotes

72

40.5

1.78

1.21 (0.60–2.44)

0.59

0.89 (0.51–1.57)

0.70

Adults

Haemoglobin variant

AA

300

936

0.32

Reference

Reference

AS

69

252

0.27

0.85 (0.56–1.30)

0.46

0.99 (0.66–1.49)

0.98

Alpha thalassaemia variant

Normal

252

783

0.32

Reference

Reference

α−/αα

102

318

0.32

1.01 (0.68–1.48)

0.98

1.10 (0.76–1.59)

0.63

α−/−α

11

70.0

0.16

0.50 (0.22–1.15)

0.10

0.58 (0.25–1.33)

0.20

G6PD genotype

Normal (male)

13

55.1

0.23

Reference

Reference

Hemizygotes

3

19.4

0.16

0.66 (0.15–2.90)

0.58

0.98 (0.16–5.85)

0.98

Normal (female)

294

995

0.30

Reference

Reference

Heterozygotes

73

191

0.38

1.26 (0.81–1.97)

0.31

1.13 (0.74–1.72)

0.58

Homozygotes

1

11.2

0.09

0.39 (0.03–4.41)

0.45

0.40 (0.04–3.92)

0.43

* Adjusted for age, average household EIR, and study site

Associations between RBC variants and prevalence of microscopic parasitaemia

The prevalence of microscopic parasitaemia at the time of routine visits across the 3 sites was 15.8% among children and 4.5% among adults. There were no significant associations between HbAS and parasite prevalence among children or adults. Children with HbSS had a 69% lower prevalence of parasitaemia compared to those with wild type genotype (PR = 0.31, 95% CI 0.18–0.54, p < 0.001) (Table 3). For both children and adults, α−/αα thalassaemia, but not α−/α− thalassaemia, was associated with a higher parasite prevalence compared to that in wild type individuals (RR = 1.23 95% CI 1.06–1.43, p = 0.008 and RR = 1.52, 95% CI 1.04–2.23, p = 0.03, respectively). For children and adults there were no significant associations between G6PD deficiency and microscopic parasitaemia (Table 3).
Table 3

Associations between RBC variants and prevalence of microscopic parasitaemia at the time of each routine visit

Age group

Red cell variants

Variant

Parasite prevalence

Unadjusted

Adjusted*

PR (95% CI)

p-value

PR (95% CI)

p-value

Children

Haemoglobin variant

AA

2488/15,830 (15.7%)

Reference

Reference

AS

597/3636 (16.4%)

1.07 (0.89–1.30)

0.46

0.95 (0.80–1.13)

0.57

SS

3/66 (4.6%)

0.31 (0.14–0.68)

0.004

0.31 (0.18–0.54)

<0.001

Alpha thalassaemia variant

Normal

1621/11,664 (13.9%)

Reference

Reference

alpha+ (α−/αα)

1272/6397 (19.9%)

1.45 (1.24–1.70)

<0.001

1.23 (1.06–1.43)

0.008

alpha0 (α−/−α)

127/937 (13.6%)

0.96 (0.66–1.40)

0.83

0.98 (0.66–1.44)

0.91

G6PD genotype

Normal (male)

1593/9147 (17.4%)

Reference

Reference

Hemizygotes

194/1030 (18.8%)

1.09 (0.81–1.48)

0.57

0.86 (0.65–1.14)

0.30

Normal (female)

887/7039 (12.6%)

Reference

Reference

Heterozygotes

372/2062 (18.0%)

1.35 (1.04–1.75)

0.02

1.13 (0.87–1.45)

0.36

Homozygotes

46/243 (18.9%)

1.38 (0.75–2.54)

0.30

0.92 (0.53–1.59)

0.76

Adults

Haemoglobin variant

AA

187/3952 (4.7%)

Reference

Reference

AS

37/1050 (3.5%)

0.72 (0.45–1.15)

0.17

0.74 (0.45–1.22)

0.24

Alpha thalassaemia variant

Normal

128/3307 (3.9%)

Reference

Reference

alpha+ (α−/αα)

81/1332 (6.1%)

1.59 (1.08–2.34)

0.02

1.52 (1.04–2.23)

0.03

α−/−α

15/290 (5.2%)

1.35 (0.76–2.42)

0.30

1.16 (0.63–2.14)

0.64

G6PD genotype

Normal (male)

8/229 (3.5%)

reference

reference

Hemizygotes

7/79 (8.9%)

2.48 (0.72–8.52)

0.15

5.10 (0.58–44.9)

0.14

Normal (female)

173/3792 (4.6%)

Reference

Reference

Heterozygotes

37/880 (4.2%)

0.87 (0.58–1.31)

0.51

0.77 (0.52–1.15)

0.20

Homozygotes

3/50 (6.0%)

1.38 (0.42–4.50)

0.59

1.34 (0.44–4.05)

0.61

* Adjusted for age, average household EIR, and study site

Associations between RBC variants and parasite densities upon infection (anti-parasite immunity) in children

Among children who were parasitaemic, the overall geometric mean parasite density was 11,400 parasites per µL (95% CI 10,800–12,100). On average, children with HbAS had lower parasite densities by a factor of 0.66 (95% CI 0.51–0.85, p = 0.001) compared to children with wild type genotype. There were no significant associations between alpha thalassaemia or G6PD deficiency and parasite densities (Table 4).
Table 4

Associations between red cell variants and parasite densities (anti-parasite immunity) in parasitaemic children

Red cell variants

Variant

Unadjusted

Adjusted*

Change in log10 parasite density (95% CI)

p-value

Change in log10 parasite density (95% CI)

p-value

Haemoglobin variant

AA

Reference

Reference

AS

− 0.25 (− 0.37, − 0.12)

< 0.001

− 0.18 (− 0.29, − 0.07)

0.001

SS

− 0.4 (− 1.33, 0.53)

0.40

− 0.11 (− 0.95, 0.73)

0.80

Alpha thalassaemia variant

Normal

Reference

Reference

α−/αα

− 0.20 (− 0.30, − 0.10)

< 0.001

− 0.06 (− 0.14, 0.03)

0.19

α−/−α

0.09 (− 0.14, 0.31)

0.45

0.04 (− 0.15, 0.22)

0.71

G6PD genotype

Normal (male)

Reference

Reference

Hemizygotes

− 0.01 (− 0.22, 0.20)

0.92

− 0.01 (− 0.18, 0.17)

0.94

Normal (female)

Reference

Reference

Heterozygotes

− 0.18 (− 0.34, − 0.01)

0.04

− 0.05 (− 0.19, 0.09)

0.51

Homozygotes

0.05 (− 0.34, 0.44)

0.80

0.12 (− 0.21, 0.45)

0.46

* Adjusted for age, average household EIR, and study site

Associations between RBC variants and body temperature upon infection (anti-disease immunity) in children

Among children who were parasitaemic, the mean tympanic temperature was 37.6 °C (IQR 37.6–37.7). In models adjusted for parasite density, parasitaemic children with HbAS had body temperatures that were on average 0.13 °C lower (95% CI, 0.05–0.21, p = 0.002) at the time of the visit, compared to children with wild type genotype. There were no significant associations between alpha thalassaemia and body temperature among parasitaemic children. Upon stratification, parasitaemic male children that were G6PD hemizygotes had temperatures that were 0.19 °C lower (95% CI 0.06–0.31, p = 0.003) compared those with the wild type G6PD genotype. There were no significant associations between G6PD deficiency and temperature among female parasitaemic children (Table 5).
Table 5

Associations between RBC variants and temperature adjusted for parasite density (anti-disease immunity) in parasitaemic children

Red cell variants

Variant

Unadjusted

Adjusted*

Change in temperature in  °C (95% CI)

p-value

Change in temperature in  °C (95% CI)

p-value

Haemoglobin variant

AA

Reference

Reference

AS

− 0.13 (− 0.22, − 0.04)

0.003

− 0.13 (− 0.21, − 0.05)

0.002

SS

0.09 (− 0.68, 0.86)

0.82

0.22 (− 0.52, 0.96)

0.56

Alpha thalassaemia variant

Normal

Reference

Reference

α−/αα

− 0.10 (− 0.17, − 0.03)

0.003

− 0.09 (− 0.21, 0.02)

0.11

α−/−α

− 0.08 (− 0.24, 0.08)

0.31

− 0.16 (− 0.41, 0.08)

0.20

G6PD genotype

Normal (male)

Reference

Reference

Hemizygotes

− 0.12 (− 0.25, 0.01)

0.07

− 0.19 (− 0.31, − 0.06)

0.003

Normal (female)

Reference

Reference

Heterozygotes

− 0.12 (− 0.24, 0.01)

0.07

− 0.09 (− 0.21, 0.02)

0.11

Homozygotes

− 0.08 (− 0.37, 0.20)

0.57

− 0.16 (− 0.41, 0.08)

0.20

* Adjusted for parasite density, age, average household EIR, and study site

Discussion

This study used data from 1322 participants enrolled in three longitudinal cohorts in Uganda to investigate associations between RBC variants and several outcomes of uncomplicated P. falciparum infection. Compared to children with wild type haemoglobin, children with HbAS had a reduced risk of incident malaria, developed lower parasite densities upon infection, and tolerated higher parasite densities without developing fever. Associations with other RBC variants were less straightforward: α−/αα thalassaemia was associated with higher parasite prevalence in both children and adults; G6PD deficient male hemizygote children, but not females, tolerated higher parasite densities without developing fever. These findings are consistent with recent findings from Uganda and elsewhere showing that HbAS is associated with protection in children, but not adults, from symptomatic malaria [2, 7, 19] and is also associated with low parasite densities during symptomatic disease [4, 19, 43]. Children with HbSS were also strongly protected against incident malaria. Furthermore, HbSS children were also less likely to develop high temperatures for any given parasite density, as compared to children with wild type haemoglobin (i.e.; they had higher anti-disease immunity). The mechanisms by which HbAS protects the host against symptomatic and severe disease have been extensively explored and appear to be complex. Some of the proposed mechanisms include increased sickling of parasitized RBCs, enhanced phagocytosis of parasitized RBCs, reduced intraerythrocytic parasite growth, and decreased cytoadherence via reduced expression of P. falciparum Erythrocyte Membrane Protein 1 (PfEMP-1) [11, 44]. The lack of protection associated with HbAS in adults is likely due to the predominant role played by acquired immunity among older age groups in highly endemic regions.

In contrast to results for HbS, there were no protective associations between alpha thalassaemia and any of the outcomes measured. In fact, although α−/αα thalassaemia has been associated with protection against both severe [5, 6, 18, 22] and uncomplicated forms of malaria [27, 28] in this study of uncomplicated malaria it was associated with a higher parasite prevalence in both children and adults as compared to the wild type. Similar associations have been previously suggested [45]. However, α−/αα thalassaemia did not have any association with incidence of symptomatic disease, parasite densities or anti-disease immunity.

Interestingly, the results from this study suggest that G6PD deficiency may play a role in anti-disease immunity. For any given parasite density, G6PD hemizygous parasitaemic male children had lower temperatures than wild type parasitaemic male children upon P. falciparum infection. Thus, G6PD deficiency may be associated with increased ability to tolerate high parasite densities without developing fever. However, the protective effect against symptomatic malaria was seen only in males, and not in heterozygous or homozygous females. There is considerable evidence to suggest that G6PD protects both male [10] and female [30, 46, 47] African children against severe malaria. However, information regarding G6PD protection from uncomplicated malaria is less clear albeit with a leaning towards protection for female children [4, 8, 24].

Results for associations between G6PD deficiency and uncomplicated malaria remain inconclusive.

This study had several limitations. First, sample sizes were small for certain groups, notably the SS and G6PD homozygous genotypes, which limited the ability to evaluate their associations with malaria outcomes. However, these genotypes occurred at expected frequencies in these populations and sample sizes would be prohibitively large to study them in a cohort. Second, parasitaemia was measured using microscopy, which is much less sensitive than molecular techniques for identifying parasites [48, 49, 50]. Impacts of RBC variants on sub-microscopic parasitaemia were not studied. Third, the degree of fever measured during symptomatic malaria may have been influenced by children receiving antipyretics prior to evaluation in the clinic. However, the majority of the patients presented to the study clinics within 24–48 h of symptom onset. Moreover, participants were encouraged to present to the clinic for all their health care needs as soon as they were unwell. Fourth, the study did not explore associations between red blood cell variants and other measures of protective immunity such as P. falciparum antibodies. Finally, there were very few cases of severe malaria, precluding exploration of associations between host polymorphisms and severe malaria.

Conclusion

In areas endemic for falciparum malaria, RBC variants may play an important role in protecting children against malaria. First, both HbAS and alpha thalassaemia are associated with decreased incidence of severe malaria. These strong associations probably explain the persistence of these balanced polymorphisms in human populations at risk of falciparum malaria. Second, some polymorphisms also appear to protect against uncomplicated malaria. Identified associations with HbAS provide the strongest evidence of protection, with evidence for lower risks of malarial incidence and enhancement of both anti-parasite and anti-disease immunity. G6PD deficiency may provide additional protection against progression to symptomatic disease, with evidence for enhanced anti-disease immunity. While the mechanisms by which common RBC variants protect against malaria remain incompletely understood, their associations with protection against malaria underline the exceptional selective pressure of malaria on the human genome.

Notes

Acknowledgements

We are grateful to the study team and the Infectious Diseases Research Collaboration for the administrative and technical support. We thank the study participants and their families for participating in the study.

Authors’ contributions

GD, MK, PJR, EA and EK conceived and designed the study. JR, AK, EK, EA, SN and AW Performed recruitment of study participants and coordinated laboratory experiments. GD, BF, JN, BG, IRB and EK performed statistical analyses and wrote the manuscript. All authors read and approved the final manuscript.

Funding

This work was funded by the National Institute of Allergy and Infectious Diseases of the National Institute of Health as part of the International Centers of Excellence in Malaria Research (ICEMR) program (Grant Number: U19AI089674). EK was funded by NIH Fogarty International Center, Training in Malaria Research in Uganda program (TW007375).

JIN is supported by the Fogarty International Center (Emerging Global Leader Award Grant Number K43TW010365. The content of the manuscript is solely the responsibility of the authors.

Ethical approval and consent to participate

The study was approved by the IRBs of all the participating institutions which included the Uganda National Council of Science and Technology (UNCST), Makerere University School of Medicine - Research and Ethical Committee (SOMREC), University of California, San Francisco Committee for Human Research (UCSF-CHR) and London School of Hygiene and Tropical Medicine Ethics Committee. Written informed consent to participate in the study was obtained from all study participants (or their designate).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Supplementary material

12936_2020_3105_MOESM1_ESM.docx (15 kb)
Additional file 1: Table S1. Prevalence of red blood cell variants stratified by study site and age group.

References

  1. 1.
    Taylor SM, Cerami C, Fairhurst RM. Hemoglobinopathies: slicing the Gordian knot of Plasmodium falciparum malaria pathogenesis. PLoS Pathog. 2013;9:e1003327.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Kwiatkowski DP. How malaria has affected the human genome and what human genetics can teach us about malaria. Am J Human Genet. 2005;77:171–92.CrossRefGoogle Scholar
  3. 3.
    Williams TN. Human red blood cell polymorphisms and malaria. Curr Opin Microbiol. 2006;9:388–94.PubMedCrossRefGoogle Scholar
  4. 4.
    Lopera-Mesa TM, Doumbia S, Konaté D, Anderson JM, Doumbouya M, Keita AS, et al. Effect of red blood cell variants on childhood malaria in Mali: a prospective cohort study. Lancet Haematol. 2015;2:e140–9.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Wambua S, Mwangi TW, Kortok M, Uyoga SM, Macharia AW, Mwacharo JK, et al. The effect of α+-thalassaemia on the incidence of malaria and other diseases in children living on the coast of Kenya. PLoS Med. 2006;3:e158.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Williams T, Wambua S, Uyoga S. Both heterozygous and homozygous thalassemia protect against severe and fatal Plasmodium falciparum malaria on the coast of Kenya. Blood. 2005;106:368–71.PubMedCrossRefGoogle Scholar
  7. 7.
    Taylor SM, Parobek CM, Fairhurst RM. Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:457–68.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Mbanefo EC, Ahmed AM, Titouna A, Elmaraezy A, Trang NTH, Long NP, et al. Association of glucose-6-phosphate dehydrogenase deficiency and malaria: a systematic review and meta-analysis. Sci Rep. 2017;7:45963.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Clark TG, Fry AE, Auburn S, Campino S, Diakite M, Green A, et al. Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility. Eur J Human Genet. 2009;17:1080–5.CrossRefGoogle Scholar
  10. 10.
    Guindo A, Fairhurst RM, Doumbo OK, Wellems TE, Diallo DA. X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria. PLoS Med. 2007;4:e66.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Gong L, Parikh S, Rosenthal PJ, Greenhouse B. Biochemical and immunological mechanisms by which sickle cell trait protects against malaria. Malar J. 2013;12:317.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Friedman MJ, Roth EF, Nagel RL, Trager W. The role of hemoglobins C, S, and Nbalt in the inhibition of malaria parasite development in vitro. Am J Trop Med Hyg. 1979;28:777–80.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Luzzatto L, Nwachuku-Jarrett E, Reddy S. Increased sickling of parasitised erythrocytes as mechanism of resistance against malaria in the sickle-cell trait. Lancet. 1970;295:319–22.CrossRefGoogle Scholar
  14. 14.
    Wajcman H, Galacteros F. [Glucose 6-phosphate dehydrogenase deficiency: a protection against malaria and a risk for hemolytic accidents](in French). C R Biol. 2004;327:711–20.PubMedCrossRefGoogle Scholar
  15. 15.
    Cappadoro M, Giribaldi G, O’Brien E, Turrini F, Mannu F, Ulliers D, et al. Early phagocytosis of glucose-6-phosphate dehydrogenase (G6PD)-deficient erythrocytes parasitized by Plasmodium falciparum may explain malaria protection in G6PD deficiency. Blood. 1998;92:2527–34.PubMedCrossRefGoogle Scholar
  16. 16.
    Le Hesran JY, Personne I, Personne P, Fievet N, Dubois B, Beyemé M, et al. Longitudinal study of Plasmodium falciparum infection and immune responses in infants with or without the sickle cell trait. Int J Epidemiol. 1999;28:793–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Verra F, Simpore J, Warimwe GM, Tetteh KK, Howard T, Osier FH, et al. Haemoglobin C and S role in acquired immunity against Plasmodium falciparum malaria. PLoS ONE. 2007;2:e978.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Mockenhaupt FP, Ehrhardt S, Gellert S, Otchwemah RN, Dietz E, Anemana SD, et al. α+-thalassemia protects African children from severe malaria. Blood. 2004;104:2003–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Williams TN, Mwangi TW, Wambua S, Alexander ND, Kortok M, Snow RW, et al. Sickle cell trait and the risk of Plasmodium falciparum malaria and other childhood diseases. J Infect Dis. 2005;192:178–86.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Gong L, Maiteki-Sebuguzi C, Rosenthal PJ, Hubbard AE, Drakeley CJ, Dorsey G, et al. Evidence for both innate and acquired mechanisms of protection from Plasmodium falciparum in children with sickle cell trait. Blood. 2012;119:3808–14.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Elguero E, Délicat-Loembet LM, Rougeron V, Arnathau C, Roche B, Becquart P, et al. Malaria continues to select for sickle cell trait in Central Africa. Proc Natl Acad Sci USA. 2015;112:7051–4.PubMedCrossRefGoogle Scholar
  22. 22.
    Mpimbaza A, Walakira A, Ndeezi G, Katahoire A, Karamagi C, Nsobya SL, et al. Associations between erythrocyte polymorphisms and risks of uncomplicated and severe malaria in Ugandan children: a case control study. PLoS ONE. 2018;13:e0203229.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Modiano D, Luoni G, Sirima BS, Simporé J, Verra F, Konaté A, et al. Haemoglobin C protects against clinical Plasmodium falciparum malaria. Nature. 2001;414:305–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Clark TD, Greenhouse B, Njama-Meya D, Nzarubara B, Maiteki-Sebuguzi C, Staedke SG, et al. Factors determining the heterogeneity of malaria incidence in children in Kampala, Uganda. J Infect Dis. 2008;198:393–400.PubMedCrossRefGoogle Scholar
  25. 25.
    Awotua-Efebo O, Alikor E, Nkanginieme K. Malaria parasite density and splenic status by ultrasonography in stable sickle-cell anaemia (HbSS) children. Niger J Med. 2004;13:40–3.PubMedGoogle Scholar
  26. 26.
    Mangano VD, Kabore Y, Bougouma EC, Verra F, Sepulveda N, Bisseye C, et al. Novel insights into the protective role of hemoglobin S and C against Plasmodium falciparum parasitemia. J Infect Dis. 2015;212:626–34.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Maitland K, Williams T, Bennett S, Newbold C, Peto T, Viji J, et al. The interaction between Plasmodium falciparum and P. vivax in children on Espiritu Santo island, Vanuatu. Trans R Soc Trop Med Hyg. 1996;90:614–20.PubMedCrossRefGoogle Scholar
  28. 28.
    Enevold A, Lusingu JP, Mmbando B, Alifrangis M, Lemnge MM, Bygbjerg IC, et al. Reduced risk of uncomplicated malaria episodes in children with alpha+-thalassemia in northeastern Tanzania. Am J Trop Med Hyg. 2008;78:714–20.PubMedCrossRefGoogle Scholar
  29. 29.
    Luzzatto L, Usanga EA, Reddy S. Glucose-6-phosphate dehydrogenase deficient red cells: resistance to infection by malarial parasites. Science. 1969;164:839–42.PubMedCrossRefGoogle Scholar
  30. 30.
    Ruwende C, Khoo S, Snow R, Yates S, Kwiatkowski D, Gupta S, et al. Natural selection of hemi-and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. Nature. 1995;376:246–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Allison A. Malaria and glucose-6-phosphate dehydrogenase deficiency. Nature. 1963;197:609.PubMedCrossRefGoogle Scholar
  32. 32.
    Segeja M, Mmbando BP, Kamugisha M, Akida J, Savaeli Z, Minja D, et al. Prevalence of glucose-6-phosphate dehydrogenase deficiency and haemoglobin S in high and moderate malaria transmission areas of Muheza, north-eastern Tanzania. Tanzania J Health Res. 2008;10:9–13.CrossRefGoogle Scholar
  33. 33.
    Kruatrachue M, Charoenlarp P, Chongsuphajaisiddhi T, Harinasuta C. Erythrocyte glucose-6-phosphate dehydrogenase and malaria in Thailand. Lancet. 1962;2:1183–6.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Jalloh A, Tantular I, Pusarawati S, Kawilarang A, Kerong H, Lin K, et al. Rapid epidemiologic assessment of glucose-6-phosphate dehydrogenase deficiency in malaria-endemic areas in Southeast Asia using a novel diagnostic kit. Trop Med Int Health. 2004;9:615–23.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Tantular I, Iwai K, Lin K, Basuki S, Horie T, Htay H, et al. Field trials of a rapid test for G6PD deficiency in combination with a rapid diagnosis of malaria. Trop Med Int Health. 1999;4:245–50.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Kamya MR, Arinaitwe E, Wanzira H, Katureebe A, Barusya C, Kigozi SP, et al. Malaria transmission, infection, and disease at three sites with varied transmission intensity in Uganda: implications for malaria control. Am J Trop Med Hyg. 2015;92:903–12.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Katureebe A, Zinszer K, Arinaitwe E, Rek J, Kakande E, Charland K, et al. Measures of malaria burden after long-lasting insecticidal net distribution and indoor residual spraying at three sites in Uganda: a prospective observational study. PLoS Med. 2016;13:e1002167.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Rodriguez-Barraquer I, Arinaitwe E, Jagannathan P, Kamya MR, Rosenthal PJ, Rek J, et al. Quantification of anti-parasite and anti-disease immunity to malaria as a function of age and exposure. Elife. 2018;7:e35832.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Kilama M, Smith DL, Hutchinson R, Kigozi R, Yeka A, Lavoy G, et al. Estimating the annual entomological inoculation rate for Plasmodium falciparum transmitted by Anopheles gambiae s.l. using three sampling methods in three sites in Uganda. Malar J. 2014;13:111.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Walakira A, Tukwasibwe S, Kiggundu M, Verra F, Kakeeto P, Ruhamyankaka E, et al. Marked variation in prevalence of malaria-protective human genetic polymorphisms across Uganda. Infection, genetics and evolution. 2017;55:281–7.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    WHO. Basic malaria microscopy—part I: learner’s guide. Geneva: World Health Organization; 2010.Google Scholar
  42. 42.
    Team RC. R: a language and environment for statistical computing. 2013.Google Scholar
  43. 43.
    Migot-Nabias F, Mombo L, Luty A, Dubois B, Nabias R, Bisseye C, et al. Human genetic factors related to susceptibility to mild malaria in Gabon. Genes Immun. 2000;1:435–41.PubMedCrossRefGoogle Scholar
  44. 44.
    Fairhurst RM, Bess CD, Krause MA. Abnormal PfEMP1/knob display on Plasmodium falciparum-infected erythrocytes containing hemoglobin variants: fresh insights into malaria pathogenesis and protection. Microbes Infect. 2012;14:851–62.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Kuesap J, Chaijaroenkul W, Rungsihirunrat K, Pongjantharasatien K, Na-Bangchang K. Coexistence of malaria and thalassemia in malaria endemic areas of Thailand. Korean J Parasitol. 2015;53:265–70.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Uyoga S, Ndila CM, Macharia AW, Nyutu G, Shah S, Peshu N, et al. Glucose-6-phosphate dehydrogenase deficiency and the risk of malaria and other diseases in children in Kenya: a case-control and a cohort study. Lancet Haematol. 2015;2:e437–44.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Orimadegun AE, Sodeinde O. Features and outcomes of malaria infection in glucose-6-phosphate-dehydrogenase normal and deficient Nigerian children. J Vector Borne Dis. 2014;51:33–9.PubMedGoogle Scholar
  48. 48.
    Rek J, Katrak S, Obasi H, Nayebare P, Katureebe A, Kakande E, et al. Characterizing microscopic and submicroscopic malaria parasitaemia at three sites with varied transmission intensity in Uganda. Malar J. 2016;15:470.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Lucchi NW, Gaye M, Diallo MA, Goldman IF, Ljolje D, Deme AB, et al. Evaluation of the illumigene malaria LAMP: a robust molecular diagnostic tool for malaria parasites. Sci Rep. 2016;6:36808.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Mens P, Spieker N, Omar S, Heijnen M, Schallig H, Kager P. Is molecular biology the best alternative for diagnosis of malaria to microscopy? A comparison between microscopy, antigen detection and molecular tests in rural Kenya and urban Tanzania. Trop Med Int Health. 2007;12:238–44.PubMedGoogle Scholar

Copyright information

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Authors and Affiliations

  • Elijah Kakande
    • 1
    Email author
  • Bryan Greenhouse
    • 2
  • Francis Bajunirwe
    • 3
  • Chris Drakeley
    • 4
  • Joaniter I. Nankabirwa
    • 1
  • Andrew Walakira
    • 1
  • Samuel L. Nsobya
    • 1
  • Agaba Katureebe
    • 1
  • John Rek
    • 1
  • Emmanuel Arinaitwe
    • 1
  • Philip J. Rosenthal
    • 2
  • Moses R. Kamya
    • 1
  • Grant Dorsey
    • 2
  • Isabel Rodriguez-Barraquer
    • 2
  1. 1.Infectious Diseases Research CollaborationKampalaUganda
  2. 2.Department of MedicineUniversity of CaliforniaSan FranciscoUSA
  3. 3.Department of Community HealthMbarara University of Science and TechnologyMbararaUganda
  4. 4.Immunity and InfectionLondon School of Hygiene & Tropical MedicineLondonUK

Personalised recommendations